This Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), is focused on developing iron-based MRI contrast agents as alternatives to gadolinium-based agents. The $305,253 award to Ferric Contrast, Inc. will fund the development and evaluation of iron coordination complexes with macrocyclic ligands to produce stable, water-soluble T1 contrast agents. The research aims to demonstrate enhanced contrast and rapid renal clearance compared to commonly used gadolinium agents, as well as track iron retention in mice over several days. The project period runs from August 1, 2025 to July 31, 2026.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $305.3k | 7/23/25 |